VSIR and cancer: The 13F3 anti-VISTA monoclonal antibody treatment significantly reduced VISTA expression on monocytes, neutrophils, macrophages, and structural cells (epithelial/endothelial), consistent with findings in cancer models where VISTA blockade enhances immune activation (27).